Skoči na glavni sadržaj

Stručni rad

RETROSPECTIVE DATA ANALYSIS OF THE PATIENTS WITH INFLAMMATORY JOINT DISEASES TREATED WITH GOLIMUMAB IN CROATIA

Branimir Anić
Đurđica Babić-Naglić
Simeon Grazio
Tatjana Kehler
Dušanka Martinović Kaliterna
Ksenija Maštrović Radončić
Jadranka Morović-Vergles
Srđan Novak
Višnja Prus
Tonko Vlak
Marko Barešić


Puni tekst: hrvatski pdf 1.199 Kb

preuzimanja: 474

citiraj


Sažetak

Golimumab is a human monoclonal antibody which inhibits
tumor necrosis factor-alpha (TNF-α) and is approved
for the treatment of infl ammatory arthritides (rheumatoid
arthritis, psoriatic arthritis and ankylosing spondylitis)
when the conventional non-pharmacological and pharmacological
therapies fail to cause remission or low disease
activity.
In this retrospective study there were included patients
with rheumatoid arthritis, psoriatic arthritis and ankylosing
spondylitis who were treated in Croatia with golimumab,
from June 2011 to June 2013. included and these retrospective
data are compared with similar data from clinical
trials and other available databases. Standard variables
of disease activity and functional ability were observed. Results demonstrated signifi cant effi cacy of golimumab
regarding lowring the disease activity and imrpving functional
ability in pateints with these infl ammatory rherumatic
disease.
In conclusion, in this retrospective study during two years
treatment golimumab showed effi cacy in decreasing disease
activity and imrpove functional ability in patiemts with
rheumatoid arthritis, psoriatic arthritis and ankylosing
spondylitis.

Ključne riječi

TNF-α inhibitors; golimumab; rheumatoid arthritis; psoriatic arthritis; ankylosing spondylitis; treatment; Croatia

Hrčak ID:

182711

URI

https://hrcak.srce.hr/182711

Datum izdavanja:

9.3.2015.

Podaci na drugim jezicima: hrvatski

Posjeta: 1.447 *